Literature DB >> 21213030

Anti-inflammatory activity of hyperimmune plasma in a lipopolysaccharide-mediated rat air pouch model of inflammation.

Bryan E Essien1, Michael Kotiw.   

Abstract

Tumour necrosis factor-α (TNFα) and polymorphonuclear neutrophils play key and interrelated roles in the inflammatory response against infectious agents. However, these entities can mediate significant tissue damage if their biological activity becomes deregulated. We have previously shown that canine hyperimmune frozen plasma (HFP) contains anti-TNFα activity that is attributable to elevated levels of soluble TNFα receptor 1 (sTNFR1). The aim of this study was to determine the effect of HFP on TNFα levels and neutrophil infiltration in a lipopolysaccharide (LPS)-mediated rat air pouch model of inflammation. Rats were administered either HFP, HFP which had been pre-incubated with anti-sTNFR1 antibody (5 ng/ml), fresh frozen plasma (FFP), physiological saline (PS) at 2 ml/day or Carprofen at 5 mg/kg for 3 days prior to LPS challenge. Pouch fluid was withdrawn at 1, 6, 12, 24 and 48 h post-LPS challenge and assayed for TNFα by ELISA, and for total leukocytes and neutrophils by microscopic examination. At 6 h post-LPS challenge, both TNFα levels and neutrophil counts were significantly lower in HFP-treated rats than was found in FFP, PS or Carprofen treated animals (p<0.05). In a sTNFR1 blocking experiment, incubation of HFP with anti-sTNFR1 antibody resulted in significant increases in neutrophil numbers and TNFα levels, which suggests that the anti-TNFα activity observed in HFP may be due to elevated levels of sTNFR1. The data also revealed a significant inverse correlation between total leukocyte counts and sTNFR1 levels present in pouch fluid (r= -0.73, p<0.0001). Our observations suggest that HFP warrants further investigation as a possible means for modulating acute inflammatory processes where TNFα is a key mediator.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21213030     DOI: 10.1007/s10753-010-9289-x

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  29 in total

1.  The role of Pseudomonas aeruginosa elastase as a potent inflammatory factor in a rat air pouch inflammation model.

Authors:  Y Kon; H Tsukada; T Hasegawa; K Igarashi; K Wada; E Suzuki; M Arakawa; F Gejyo
Journal:  FEMS Immunol Med Microbiol       Date:  1999-08-15

2.  Immunomodulatory effects of etanercept in an experimental model of spinal cord injury.

Authors:  Tiziana Genovese; Emanuela Mazzon; Concetta Crisafulli; Rosanna Di Paola; Carmelo Muià; Placido Bramanti; Salvatore Cuzzocrea
Journal:  J Pharmacol Exp Ther       Date:  2005-11-22       Impact factor: 4.030

3.  The effect of anti-inflammatory and rheumatoid disease modifying drugs on prolonged immune and non-immune inflammation in the six-day air pouch of rats.

Authors:  A Y Al-Duaij; A D Sedgwick; D A Willoughby
Journal:  Int J Tissue React       Date:  1986

Review 4.  Crosstalk between NF-kappaB-activating and apoptosis-inducing proteins of the TNF-receptor complex.

Authors:  K Heyninck; R Beyaert
Journal:  Mol Cell Biol Res Commun       Date:  2001-09

5.  Prolonged inflammatory reactions induced by artificial ceramics in the rat air pouch model.

Authors:  M Nagase; D G Baker; H R Schumacher
Journal:  J Rheumatol       Date:  1988-09       Impact factor: 4.666

6.  Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes.

Authors:  Silvia Kirchner; Ernst Holler; Silvia Haffner; Reinhard Andreesen; Günther Eissner
Journal:  Cytokine       Date:  2004-10-21       Impact factor: 3.861

Review 7.  Anti-tumor necrosis factor nonresponders in Crohn's disease: therapeutic strategies.

Authors:  E Louis; J Belaiche; C Reenaers
Journal:  Dig Dis       Date:  2009-09-24       Impact factor: 2.404

8.  Detection of anti-TNFalpha activity in canine hyperimmune serum using a TNFalpha inhibition assay.

Authors:  Michael Kotiw; Michael Morgan; Stephen M Taylor; Ian A Shiels
Journal:  Vet Clin Pathol       Date:  2009-07-01       Impact factor: 1.180

9.  Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo.

Authors:  K J Van Zee; T Kohno; E Fischer; C S Rock; L L Moldawer; S F Lowry
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

10.  Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis.

Authors:  Wolfgang Hueber; Beren H Tomooka; Franak Batliwalla; Wentian Li; Paul A Monach; Robert J Tibshirani; Ronald F Van Vollenhoven; Jon Lampa; Kazuyoshi Saito; Yoshiya Tanaka; Mark C Genovese; Lars Klareskog; Peter K Gregersen; William H Robinson
Journal:  Arthritis Res Ther       Date:  2009-05-21       Impact factor: 5.156

View more
  4 in total

1.  Effects of analgesic use on inflammation and hematology in a murine model of venous thrombosis.

Authors:  Gerald A Hish; Jose A Diaz; Angela E Hawley; Daniel D Myers; Patrick A Lester
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-09       Impact factor: 1.232

2.  Possible role of lymphocytes in glucocorticoid-induced increase in trabecular bone mineral density.

Authors:  Louise Grahnemo; Caroline Jochems; Annica Andersson; Cecilia Engdahl; Claes Ohlsson; Ulrika Islander; Hans Carlsten
Journal:  J Endocrinol       Date:  2014-10-30       Impact factor: 4.286

3.  Imaging windows for long-term intravital imaging: General overview and technical insights.

Authors:  Maria Alieva; Laila Ritsma; Randy J Giedt; Ralph Weissleder; Jacco van Rheenen
Journal:  Intravital       Date:  2014-08-11

4.  GPR105-Targeted Therapy Promotes Gout Resolution as a Switch Between NETosis and Apoptosis of Neutrophils.

Authors:  Chunxiao Liu; Mengze Zhou; Wenjiao Jiang; Shumin Ye; Sheng Tian; Cheng Jiang; Kun Hao; Huanqiu Li; Qinghua Hu
Journal:  Front Immunol       Date:  2022-03-30       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.